Reactive arthritis is a type of arthritis that develops secondary to infections in other parts of the body (such as the intestinal and genitourinary tracts). It is most commonly seen in young men, is associated with HLA-B27, and belongs to the rheumatology category of spondyloarthropathies. There is no specific or curative treatment available, and the aim of its treatment is to control and relieve pain, prevent joint destruction, and protect joint function. The treatment of reactive arthritis is described as follows: 1. General treatment: acute arthritis can be bed rest, and functional joint exercises should be started as soon as possible after the acute inflammation is relieved. Fixed joint splinting should be avoided to avoid causing fibrous ankylosis and muscle atrophy. 2, non-steroidal anti-inflammatory drugs: this class of drugs can reduce joint swelling and pain, increase the range of motion of the joint, is the first choice of patients with a wide range of drugs, but the efficacy is roughly equivalent, the specific choice can vary from person to person, but pay attention to its adverse reactions. The use of antibiotics (ofloxacin or macrolide antibiotics) for short-term treatment of concomitant urinary tract infections may reduce the risk of recurrent arthritis in patients with a history of ReA, but there is no evidence of benefit to existing arthritis itself, and long-term antibiotic therapy is not recommended for chronic ReA. It is not recommended to be used after the onset of ReA. Glucocorticoids: Glucocorticoids can be used for a short period of time for individual patients whose symptoms cannot be relieved by NSAIDs, but oral treatment can neither stop the development of the disease nor bring about many adverse effects. Topical glucocorticoids and keratolytics are effective in overflowing septic keratosis. Intra-articular glucocorticoid injections can temporarily relieve swelling of the knee and other joints. Pain and pressure caused by the plantar fascia or Achilles bursa can be treated with local glucocorticoid injections to allow early movement of the ankle joint to avoid shortening and fibrous ankylosis of the Achilles tendon. Attention must be paid to avoid direct injection into the Achilles tendon to prevent rupture of the Achilles tendon. 5, slow-acting anti-rheumatic drugs: when non-steroidal anti-inflammatory drugs cannot control arthritis, joint symptoms persist for more than 3 months or there is evidence of joint destruction, slow-acting anti-rheumatic drugs can be added, such as salazosulfapyridine, methotrexate, azathioprine and other immunosuppressive drugs. 6, biological agents: tumor necrosis factor inhibitors have been successfully used to treat other types of spondyloarthropathies, such as ankylosing spondylitis, psoriatic arthritis, etc., but there is a lack of randomized controlled studies to verify the effectiveness and safety of ReA. Some open studies or case reports in small samples suggest that it may be effective. The natural course of ReA varies from person to person, with most first-episode oligoarthritis resolving within 3-6 months, complete remission in 75% of patients after 2 years, and a further 10%-15% of patients who may have the disease for more than 2 years, and an additional 1% of patients, particularly those with overflowing cutaneous keratoses, who may have a worse prognosis. Longer-term follow-up reveals that 3-4 years after the first onset some patients may experience a recurrence of symptoms including peripheral arthritis, tendon telangiectasia, iritis, or other extra-articular symptoms. Approximately 10% of patients progress to ankylosing spondylitis. Hip involvement, persistent elevated ESR, and poor response to NSAIDs suggest a poor prognosis. death from ReA is rare and is usually due to cardiac complications or amyloidosis.